Big congratulations to our portfolio company Thermosome on the approval by the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible ethics committee to conduct a phase 1 trial with its lead program THE001 in patients with soft tissue sarcoma.

THE001 is a thermosensitive liposomal formulation of the chemotherapeutic drug doxorubicin (DPPG2-TSL-DOX).
It has a different mode of action than conventional liposomes which enables intravascular drug release initiated by a mild heat trigger using clinically established hyperthermia devices. This results in up to 15-fold higher local drug concentrations and improves efficacy by creating a local boost at the desired site of action.
We keep our fingers crossed and hope that this approach will quickly find its way to patients.
More information in the press release under the following Link
More about Themosome